((自动化翻译由路透提供，请见免责声明 ))
11月4日 - ** 药物开发商Disc Medicine 股价上涨约28.6%，至60.60美元，创3月份以来新高
** 该公司称，美国食品及药物管理局（FDA）对其遗传性疾病药物比托哌汀（bitopertin）的试验设计给予了积极的 (link)。
** Bitopertin 正在开发用于治疗红细胞生成性原卟啉症$(EPP.UK)$，这是一种罕见的遗传性代谢紊乱。
** IRON 称，根据现有数据，该药物有可能获得 FDA 的加速批准
** BMO Capital Markets 表示："审批时间表的改善和确认性试验设计的明确化对 IRON 股价构成重大利好。
** 股价年初至今上涨 15.1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.